| Project/Area Number |
06454599
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Biological pharmacy
|
|---|
| Research Institution | University of Tokusihma |
|---|
Principal Investigator |
TERADA Hiroshi University of Tokushima Faculty of Pharmaceutical Sciences, Professor, 薬学部, 教授 (00035544)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SHINOHARA Yasuo University of Tokushima Faculty of Pharmaceutical Sciences, Associate Professor, 薬学部, 助教授 (60226157)
|
|---|
| Project Period (FY) |
1994 – 1995
|
| Project Status |
Completed (Fiscal Year 1995)
|
| Budget Amount *help |
¥6,800,000 (Direct Cost: ¥6,800,000)
Fiscal Year 1995: ¥2,600,000 (Direct Cost: ¥2,600,000)
Fiscal Year 1994: ¥4,200,000 (Direct Cost: ¥4,200,000)
|
|---|
| Keywords | type II hexokinase / tumor cells / energy metabolism / sugar metabolism / mitochondria / transcriptional control / gene expression / ヘキソキナーゼ / ADP / ATP carrier |
|---|
| Research Abstract |
In our previous study, we found that the steady state transcript level of type II hexokinase was specifically and remarkably enhanced in rat tumor cell line, AH130. In this study, first of all, to confirm the universality of the enhanced expression of type II hexokinase in tumor cells, we examined its transcript levels in human tumor cell lines and transformed cell lines. As a result, increment in the transcript level of type II hexokinase in malignant tumor cells was reconfirmed. Next, to understand the molecular mechanisms in the specific increment of type II hexokinase in tumor cells, we carried out several experiments and obtained following results.
1) To understand the molecular mechanism of the transcriptional activation of type II hexokinase in tumor cells, we isolated the promoter region of the gene encoding this hexokinase isozyme and characterized its structural feature and transcriptional activity.
2) To know the functional difference between type II hexokinase and the other hexokinase isozymes, we examined the functional feature of type II hexokinase.
3) To understand the physiological meaning of the binding of type II hexokinase molecule on mitochondria observed in tumor cells, we examined the functional characteristics of the hexokinase bound to tumor mitochondria. Results showed the preferential use of ATP generated by oxidative phosphorylation than that exist in cytosol by hexokinase bound to tumor mitochondria.
|
